We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

UC Study Links Ketogenic Diet to Reduced MS Symptoms

Food products that are keto.
Credit: iStock.
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 3 minutes

Research has long hinted that the ketogenic diet may help manage autoimmune diseases like multiple sclerosis (MS) by dampening overactive immune responses. A new study from the University of California, San Francisco (UCSF) has offered promising evidence to support this theory. Scientists found that, in a mouse model of MS, the keto diet induced the production of specific compounds in the gut, which helped to reduce MS symptoms. If these findings hold true in humans, the research could open the door to new treatment approaches for autoimmune disorders using diet-based supplements rather than strict dietary restrictions.

The ketogenic diet and immune modulation

The ketogenic (keto) diet involves severely limiting carbohydrate intake while increasing fat consumption, causing the body to shift from burning carbohydrates for energy to breaking down fat. This shift results in the production of ketone bodies, which serve as an alternative fuel source and have been shown to influence immune function. The UCSF team’s findings, published in Cell Reports, provide insight into how this dietary shift impacts immune-related inflammation.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

Key findings: ketones, bacteria, and immune regulation

The study showed that a ketone body known as β-hydroxybutyrate (βHB) played a central role in reducing inflammation in mice. In the study, mice on a keto diet produced higher levels of βHB, which in turn affected the activity of gut bacteria. Specifically, the gut bacterium Lactobacillus murinus responded to βHB by producing a compound called indole lactic acid (ILA), which blocked the activation of T helper 17 (Th17) cells. These Th17 cells are commonly involved in MS and other autoimmune diseases, where they drive immune-related inflammation.


β-hydroxybutyrate (βHB)

A ketone body produced when the body breaks down fat for energy in low-carbohydrate conditions. βHB serves as an alternative energy source and has been linked to various anti-inflammatory effects in the body.

T helper 17 (Th17) cells

A type of immune cell involved in inflammation, especially in autoimmune diseases. Th17 cells can contribute to disease progression in conditions such as multiple sclerosis and rheumatoid arthritis.

Indole lactic acid (ILA)

A metabolite produced by certain gut bacteria, including Lactobacillus murinus. ILA has been shown to reduce immune activation and may play a role in regulating inflammatory responses in the gut.

Lactobacillus murinus

A bacterial species found in the gut microbiome, known for its ability to produce compounds that interact with the immune system. L. murinus has been studied for its potential in modulating immune responses, especially in the context of inflammation.

Experimental results: supplementing βHB and isolating bacteria

To understand the gut’s role in this process, the researchers first examined mice unable to naturally produce βHB in their intestines. These mice exhibited more severe inflammatory symptoms compared to those that could produce the compound. However, supplementing the diets of these βHB-deficient mice with additional βHB reduced their inflammation levels, showing that βHB’s presence is critical in managing immune responses in the gut.


The team further investigated by isolating bacterial strains from the intestines of mice on different diets (keto, high-fat, and βHB-supplemented high-fat diets). They found that mice on the βHB-supplemented diets had higher levels of L. murinus, which produced ILA – a metabolite shown to interact with the immune system and reduce inflammation. Genome sequencing and mass spectrometry confirmed that L. murinus specifically was responsible for producing ILA.

Testing potential treatments with ILA and L. murinus

The team explored whether treating the MS mice with either ILA or L. murinus would directly affect disease severity. Results indicated that both treatments helped reduce MS symptoms in the mice, suggesting that specific bacterial compounds might offer a therapeutic benefit. However, as lead researcher Peter Turnbaugh, PhD, cautions, these effects still need testing in humans to confirm their efficacy and safety.

Future directions and implications for treatment

This study’s findings highlight the potential of using keto-related supplements to mimic some benefits of the diet without requiring strict adherence to dietary restrictions. For patients with autoimmune disorders, a supplement-based approach might offer a more accessible and tolerable option. Turnbaugh emphasized that while the results are promising, further research is necessary to understand how this approach might apply in clinical settings.


“The big question now is how much of this will translate into actual patients. But I think these results provide hope for the development of a more tolerable alternative to helping those people than asking them stick to a challenging and restrictive diet.”

Dr. Peter Turnbaugh

With additional testing in humans, this research could lead to new options for people with autoimmune diseases, allowing them to gain the immune-modulating effects of a keto diet without the need for strict dietary limitations.


Reference: Alexander M, Upadhyay V, Rock R, et al. A diet-dependent host metabolite shapes the gut microbiota to protect from autoimmunity. Cell Reports. 2024:114891. doi: 10.1016/j.celrep.2024.114891


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.


This content includes text that has been generated with the assistance of AI. Technology Networks' AI policy can be found here.